Exact Sciences Co. (NASDAQ:EXAS) Holdings Lifted by Bamco Inc. NY

Bamco Inc. NY lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 42.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 893,000 shares of the medical research company's stock after purchasing an additional 265,000 shares during the quarter. Bamco Inc. NY owned about 0.48% of Exact Sciences worth $50,178,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in EXAS. ArrowMark Colorado Holdings LLC grew its holdings in Exact Sciences by 4.6% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 439,487 shares of the medical research company's stock valued at $24,695,000 after buying an additional 19,528 shares during the period. Mercer Global Advisors Inc. ADV increased its position in Exact Sciences by 4.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 39,488 shares of the medical research company's stock worth $2,219,000 after purchasing an additional 1,589 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new position in Exact Sciences during the fourth quarter worth approximately $837,000. Soros Fund Management LLC boosted its holdings in shares of Exact Sciences by 31.3% in the 4th quarter. Soros Fund Management LLC now owns 496,938 shares of the medical research company's stock valued at $27,923,000 after purchasing an additional 118,348 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of Exact Sciences by 384.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 21,708 shares of the medical research company's stock valued at $1,220,000 after buying an additional 17,231 shares during the period. Hedge funds and other institutional investors own 88.82% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EXAS shares. William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Scotiabank boosted their target price on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Piper Sandler cut their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Evercore ISI boosted their price objective on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Finally, Guggenheim restated a "buy" rating and set a $60.00 target price on shares of Exact Sciences in a report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $70.90.

Exact Sciences Stock Performance

Shares of EXAS traded down $1.34 during mid-day trading on Friday, hitting $51.72. The stock had a trading volume of 1,975,118 shares, compared to its average volume of 2,645,894. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a market cap of $9.76 billion, a PE ratio of -9.29 and a beta of 0.92. Exact Sciences Co. has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The company's fifty day simple moving average is $45.47 and its two-hundred day simple moving average is $52.96.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $706.79 million during the quarter, compared to analyst estimates of $688.58 million. During the same quarter in the previous year, the firm earned ($0.60) earnings per share. The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.